Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor
Crossref DOI link: https://doi.org/10.1007/s13318-017-0403-4
Published Online: 2017-02-24
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hussein, Ziad
Mizuo, Hitoshi
Hayato, Seiichi
Namiki, Masayuki
Shumaker, Robert
Funding for this research was provided by:
Eisai Inc
License valid from 2017-02-24